End-stage kidney disease necessitating dialysis

1. Statin + fenofibrate is associated with end-stage kidney disease necessitating dialysis in humans (HR 0.79, 95% CI 0.67–0.92).

   “and ESKD necessitating dialysis (264 [8.3%] vs 335 [10.5%]; HR, 0.79; 95% CI, 0.67-0.92).”

   HumansNon-dialysis-dependent CKD, hypertriglyceridemia, and ischemic heart disease; compared with statin monotherapymedian 881 days with combination therapy and 925 days with statin monotherapy

   Combined statin and fenofibrate therapy and cardiorenal outcomes in patients with CKD, dyslipidemia, and ischemic heart disease

   Clinical kidney journal·1 Oct 2026

More on Statin + fenofibrate